Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Artificial intelligence is generating a new generation of biomarkers. But which ones are ready for clinical use?
The ESMO EBAI framework classifies AI-based biomarkers into 3 tiers and defines the minimum validation requirements for each. A critical step toward safe clinical integration.”
Title: ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
Authors: M. Aldea, M. Salto-Tellez, A. Marra, R. Umeton, A. Stenzinger, M. Koopman, A. Prelaj, K. L. Kehl, S. Gilbert, M.-E. Leßmann, J. Lipkova, L. Provenzano, F. Meric-Bernstam, S. Halabi, J. Wu, A. Pellat, K. P. M. Suijkerbuijk, B. Besse, B. Ryll, C. Marchió, M. Crispin-Ortuzar, R. Fehrmann, J. Vibert, D. Ferber, C. Pauli, A. Valachis, F. Corso, T. J. Brinker, J. Mateo, N. Harbeck, E. C. Winkler, F. Lopez-Rios, R. Perez-Lopez, G. Pentheroudakis, S. Delaloge, C. Benedikt Westphalen, J. N. Kather
Read The Full Article
Other articles about ESMO on OncoDaily.